Loading news...
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving th.
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket trading.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th.
Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating on the
Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $13.62 and last traded at $13.80, with a volume of 29533 shares traded. The stock had previously closed at $13.83. Wall Street Analysts Forecast Growth JANX has been
SAN DIEGO--(BUSINESS WIRE)--Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and cohort expansion.
Capital Fund Management S.A. purchased a new stake in Janux Therapeutics, Inc. (NASDAQ: JANX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,772 shares of the company's stock, valued at approximately $757,000. Capital Fund Management S.A. owned 0.05% of
Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics (JANX 1.70%), exercised 16,665 options and immediately sold the resulting shares for a transaction value of approximately $501,000 on October 28, 2025, according to a recent SEC Form 4 filing.
Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).
Shares of Janux Therapeutics slumped nearly 50% on Tuesday as investors reacted to limited disclosure in the company's early-stage study update for its prostate cancer treatment.
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Janux posts what it called ‘positive trial data' for its novel treatment in patients with late-stage prostate cancer.
Ensign Peak Advisors Inc reduced its position in Janux Therapeutics, Inc. (NASDAQ: JANX) by 96.8% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,300 shares of the company's stock after selling 285,450 shares during the quarter. Ensign Peak Advisors Inc's
Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC.
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced it will host a virtual event on Monday, December 1, 2025, at 4:30 PM ET. David Campbell, Ph.D., President & Chief Execu.
Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the sixteen analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating